Approval Application for Gilead’s Novel Booster Cobicistat Filed with FDA A day after Gilead Sciences filed a New Drug Application (NDA) for its integrase inhibitor elvitegravir, the company announced on June 28 that it has submitted all the necessary paperwork to the U.S. Food and Drug Administration requesting approval for its experimental pharmacoenhancing agent cobicistat.
June 27, 2012
HIV/Hep C Coinfection and Each Virus by Itself Increase Hip Fracture Risk
People living with HIV and hepatitis C virus (HCV) coinfection are more likely to experience a hip fracture as a result of decreased bone mineral density, compared with people not infected with either virus or those living with either HIV or HCV, according to the results of a large prospective study involving Medicaid recipients published online ahead of print by the journal Hepatology. The study also confirms that people living with either HIV or HCV are significantly more likely to experience a hip fracture than those negative for both viruses.
HIV Treatment May Lower Risk of Precancerous Anal Lesions
Potential good news for HIV-positive men who have sex with men: Antiretroviral therapy may reduce the prevalence of precancerous anal lesions and infection with the cancer-causing human papillomavirus (HPV), according to a new study published in the July issue of the journal Sexually Transmitted Diseases.
June 22, 2012
HIV-Positive and -Exposed Children More Likely to Have Hearing Loss Children exposed to HIV in the womb may be more likely to experience hearing loss by age 16 than their unexposed peers, according to new research published online ahead of print by The Pediatric Infectious Disease Journal and summarized in a National Institutes of Health (NIH) news announcement.
June 20, 2012
Lower Bone Mass in Adolescents With HIV Raises Concerns
Male teens and young adults recently infected with HIV and currently receiving antiretroviral therapy have lower bone mass than HIV-negative individuals their age, according to the results of an Adolescent Trials Network (ATN) study published ahead of print by Clinical Infectious Diseases
June 19, 2012
Efavirenz Bests Nevirapine as First-Line Treatment in U.S.-Euro Study Compared with nevirapine (Viramune), efavirenz (the active ingredient in Sustiva and a component of Atripla) appears to be associated with better survival, fewer AIDS-related opportunistic infections and a decreased likelihood of experiencing virologic failure among first-time treatment takers. These are the findings of a large cohort study published ahead of print by the journal AIDS.
June 15, 2012
New HIV Diagnoses Among Latinos Decline in U.S.
The rate of new HIV diagnoses among Latinos in the United States decreased by more than 4 percent annually between 2006 and 2009, according to a new report by U.S. Centers for Disease Control and Prevention (CDC) researchers published in the June 1 issue of the Journal of Acquired Immune Deficiency Syndromes.
June 14, 2012
HIV Therapy Decreases Bone Fracture Risk, Compared With Those Not on Treatment Compared with people living with HIV and not being treated for it, those using antiretroviral (ARV) therapy are less likely to experience a fracture related to frail bones, according to a research paper authored by Linda Mundy, MD, of GlaxoSmithKline and her colleagues, published in the June 1 issue of the journal AIDS.
June 13, 2012
1 in 4 Los Angeles Homeless Have Hep C Nearly 27 percent of homeless adults surveyed and tested in downtown Los Angeles’ skid row were infected with hepatitis C virus (HCV)—more than 10 times the 2 percent rate among the general U.S. population—according to a new study by University of California at Los Angeles (UCLA) researchers published in the July/August 2012 issue of Public Health Reports.
HIV Drug Selzentry Shows Breast Cancer Treatment Potential Drugs that block the CCR5 receptor on cells—such as HIV med Selzentry (maraviroc)—may also help prevent aggressive breast cancers from spreading and causing lethal disease, according to new research conducted at Kimmel Cancer Center of Thomas Jefferson University in Philadelphia and published in a recent issue of Cancer Research.
June 12, 2012
HIV Material Detected in Berlin Patient Samples Spurs Cure Questions, Confusion
Does a recent conference presentation noting that HIV genetic material has been detected at low levels, in a minority of recent samples taken from Timothy Brown, a.k.a. “the Berlin Patient,” debunk the conclusion that he has been cured of the infection? While one scientist is publicly arguing that Brown “still has detectable HIV in his body” and goes so far to suggest that he may even have been reinfected, others—including the original study presenters—counter that these claims misrepresent the new data and are therefore misleading.
June 11, 2012
Truvada HIV PrEP Approval Decision Delayed Three Months The U.S. Food and Drug Administration has extended its review of Gilead Sciences’ approval application for Truvada (tenofovir plus emtricitabine) as pre-exposure prophylaxis (PrEP), according to a June 6 announcement by the company. Whereas an approval decision was originally expected by this Friday, June 15, the agency now has until September 14 to make its final determination.
HIV-Targeting Protein Identified by NIH Scientists
Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health have identified yet another cellular protein to be explored for HIV drug development: CXCL4. The research, authored by Paolo Lusso, MD, PhD, of the institute's Laboratory of Immunoregulation and his colleagues, is published online ahead of print by the Proceedings of the National Academy of Sciences of the United States of America (PNAS).